A Phase 3 interventional study of Olokizumab 64 mg SC q4w and Olokizumab 64 mg SC q2w in Rheumatoid Arthritis, sponsored by R-Pharm International, LLC. Completed at 239 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-12.
Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 9th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2017.
This study's enrollment of 2,106 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 206 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under R-Pharm International, LLC, one of the names counted as R-Pharm. Under that name alone:
R-Pharm International, LLC is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
R-Pharm has 5 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA) who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3 (core studies). The long-term efficacy, immunogenicity, the physical function and quality of life of subjects received long-term treatment with OKZ were assessed as well.
This OLE study (CL04041024) included an 82-week open-label Treatment Period that followed completion of one of the core studies (Study CREDO 1, 2 or 3). The OLE open-label Treatment Period lasted from Visit 1 (OLE Baseline/Week 24) to Visit 10 (End of Treatment (EoT)/Week 106), followed by a 20-week Safety Follow-Up Period from Week 106 to Week 126. The first visit of the OLE study was the same visit as the Week 24 visit in the core studies.
Subjects were randomized to 1 of the 2 OKZ treatment groups in the OLE study based on the treatment received in the core studies. Subjects who had received OKZ (q2w or q4w) in the core study in which they had participated (including subjects who received placebo in Study CREDO 3 and were re-randomized to OKZ at Week 16) received the same OKZ treatment regimen in the OLE study. Subjects who had received placebo (Study CREDO 1 and CREDO 2) or adalimumab (Study CREDO 2) in the core study in which they had participated were randomized in a 1:1 ratio to OKZ 64 mg q2w or OKZ 64 mg q4w regimens in the OLE study.
For the first 12 weeks of the OLE, all subjects were required to remain on a stable dose of background methotrexate (MTX) at 15 to 25 mg/week (or≥10 mg/week if there was documented intolerance to higher doses) with a stable route of administration (oral, SC, or intramuscular (IM)). After 12 weeks (Visit 4 [Week 36] of the OLE study), the Investigator might adjust the MTX dosage and route, per local guidelines. Methotrexate might be adjusted only for safety reasons according to Investigator discretion before Visit 4 (Week 36) of the OLE study.
Subjects who had been on rescue disease-modifying anti-rheumatic drugs (DMARDs) during the core studies were asked to continue these medications for the first 12 weeks of the OLE study. The Investigator could adjust these background medications if deemed appropriate after Visit 4 (Week 36) of the OLE study. Background rescue therapy might be adjusted only for safety reasons according to Investigator discretion before Visit 4 (Week 36) of the OLE study.
Throughout the study, concomitant treatment with folic acid ≥ 5 mg per week or equivalent was required for all subjects.
Subjects returned to the study site periodically for safety and response assessments as per the Schedule of Events.
The last dose of open-label study treatment in the OLE study was administered at Week 104 for all subjects. After completion of the 82-week open-label Treatment Period, subjects entered the 20-week Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for 3 visits at +4, +8, and +22 weeks after the last dose of study treatment.
Subjects who discontinued the open-label treatment prematurely required to come for the EoT Visit 2 weeks after the last study treatment administration and then return for the 3 Safety Follow-Up Visits +4, +8, and +22 weeks after the last study treatment administration.
Adverse events were assessed throughout the study period and evaluated using the Common Technology Criteria version 4.0 (CTCAE v 4.0).
There were ongoing monitoring of safety events, including laboratory findings by the Sponsor or its designee. In addition, safety parameters were assessed throughout the study by an independent Data Safety Monitoring Board (DSMB).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects may be enrolled in the study only if they meet all of the following criteria:
Exclusion Criteria:
Subject with a positive or repeated indeterminate interferon-gamma release assay (IGRA) result at Week 22 of the core study
Female subjects of (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol \<20 pg/mL) who are not willing to use a highly effective method of during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment.
Highly effective contraception is defined as:
Female sterilization surgery: hysterectomy, surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks prior to the first dose of study treatment in the core study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olokizumab 64 mg SC q4w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
Drug: Olokizumab 64 mg SC q4w · Drug: Concomitant treatment
Olokizumab 64 mg SC q2w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
Drug: Olokizumab 64 mg SC q2w · Drug: Concomitant treatment
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.) Folic acid ≥ 5 mg per week or equivalent
Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)
Incidence of Treatment-Emergent Adverse Events Reported for ≥5% of Subjects in Any Treatment Group by System Organ Class or Preferred Term
Time frame: up to Week 126
Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population)
Incidence of Serious Treatment-Emergent Adverse Events by System Organ Class or Preferred Term. Deaths are included.
Time frame: up to Week 126
Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI)
Time frame: up to Week 126
Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment
Time frame: up to Week 126
Incidence Rate of Treatment Emergent AEs Per Patient-years of Exposure
Incidence Rate of all Subjects with at Least One Treatment Emergent AE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.
Time frame: up to Week 126
Incidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure
Incidence Rate of all Subjects with at Least One Treatment Emergent SAE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.
Time frame: up to Week 126
Incidence Rate of Treatment Emergent AESIs (Safety Population)
Incidence Rate of all Subjects with at Least One Treatment Emergent AESI. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.
Time frame: up to Week 126
American College of Rheumatology 20% (ACR20) Response Rates Compare Against Core Baseline Through Week 82
Number and Proportion of subjects achieving an ACR20 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: up to Week 82
American College of Rheumatology 50% (ACR50) Response Rates Compare Against Core Baseline Through Week 82
Number and Proportion of subjects achieving an ACR50 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 50 % response is a composite defined as a ≥ 50% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: up to Week 82
American College of Rheumatology 70% (ACR70) Response Rates Compare Against Core Baseline Through Week 82
Number and Proportion of subjects achieving an ACR70 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 70 % response is a composite defined as a ≥ 70% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 70% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
Time frame: up to Week 82
Proportion of Subjects With Simplified Disease Activity Index (SDAI) Remission Through Week 82
The number and proportion of subjects with SDAI score ≤ 3.3 (considered to be in remission). The SDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), CRP (mg/dL), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS) + CRP (mg/dL)
Time frame: up to week 82
Disease Activity Score 28-joint Count (DAS28) Response Rates Through Week 82
Number and Proportion of subjects with DAS28 low disease activity (based on DAS28 C-reactive protein (CRP) \< 3.2), who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. The DAS28 (CRP) was calculated in the statistical database for analysis purposes using the Swollen joint count (SJC) (28 joints), Tender joint count (TJC) (28 joints), CRP level, and the Patient Global Assessment of Disease Activity Visual Analog Scale (VAS) (100 mm VAS, where 0 is "no disease activity" and 100 was "maximal disease activity") according to the following formula: \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.36 × natural log (CRP+1)\] + \[0.014 × VAS\] + 0.96.
Time frame: up to Week 82
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 12
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: Core baseline, Week 12
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 20
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: Core baseline, Week 20
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 28
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: Core baseline, Week 28
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 40
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: Core baseline, Week 40
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 52
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: Core baseline, Week 52
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 64
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: Core baseline, Week 64
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 82
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: Core baseline, Week 82
Proportion of Subjects With Health Assessment Questionnaire - Disability Index (HAQ-DI) Improvement Through Week 82
The number and proportion of subjects with HAQ-DI improvement ≥ 0.22 Against OLE Baseline. HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
Time frame: up to week 82
Changes From Core Baseline Over Time in Clinical Disease Activity Index (CDAI)
CDAI Range: 0 (the best outcome) - 76 (the worst outcome), with a decrease from baseline indicating improvement. The CDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: CDAI = SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS)
Time frame: up to week 82
Enrollment was conducted at 241 sites in 18 countries (Argentina, Belarus, Bulgaria, Brazil, Colombia, Czech Republic, Germany, Estonia, United Kingdom, Hungary, South Korea, Lithuania, Latvia, Mexico, Poland, Russia, Taiwan, United States). A total of 2105 subjects who had previously completed 24 weeks of double-blind treatment in a core study were randomized. All except one randomized subject received OKZ treatment. A total of 2104 subjects were analyzed for efficacy in the mITT Population.
| Milestone | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Started | 1058 | 1047 |
| Mitt | 1057 | 1047 |
| Safety population | 1043 | 1061 |
| Completed | 830 | 844 |
| Not completed | 228 | 203 |
| Withdrew: Randomized in error | 1 | 0 |
| Withdrew: Death | 13 | 13 |
| Withdrew: Lost to follow-up | 23 | 13 |
| Withdrew: Withdrawal by subject | 139 | 124 |
| Withdrew: Covid-19 | 43 | 34 |
| Withdrew: Patient moved out of residence and was not able to come to the site | 1 | 3 |
| Withdrew: Lack of discipline in adhering to the schedule of visits, difficult cooperation with the patient | 1 | 0 |
| Withdrew: Safety follow-up visit (sfu)-3 was performed by phone due to family reasons | 1 | 0 |
| Withdrew: Patient completed the treatment, but could not come for follow-up visits due to another city moving | 1 | 0 |
| Withdrew: Site was closed | 2 | 3 |
| Withdrew: Study coordinator error, patient started a biologic and study coordinator forgot to complete sfu | 1 | 0 |
| Withdrew: Principal investigator (pi) decision, the pi starting subject on another biologic medication | 0 | 1 |
| Withdrew: Pi terminated subject from ip (ae's abnormal wbc, abnormal absolute neutrophils lab) | 1 | 0 |
| Withdrew: Patient was hospitalized due to the sae and couldn't visit the site for sfu-3 | 1 | 0 |
| Withdrew: Other: adverse event | 0 | 1 |
| Withdrew: Due to the death of his wife, he refused to participate in follow up 3 | 0 | 1 |
| Withdrew: Follow up visit not performed (patient outside residence) | 0 | 2 |
| Withdrew: Subject refusal to attend visit | 0 | 1 |
| Withdrew: Personal reasons | 0 | 1 |
| Withdrew: Pi did not feel it was best for subject to be without treatment for 12 weeks. | 0 | 1 |
| Withdrew: Lack of efficacy (pi perspective) end of study visit | 0 | 1 |
| Withdrew: Compliance with medication | 0 | 1 |
| Withdrew: Subject has a severe or life threatening infection that requires hospitalization per medical monitor | 0 | 1 |
| Withdrew: Other: protocol violation (refused from sfu visits) | 0 | 1 |
| Withdrew: Study terminated by principal investigator | 0 | 1 |
Incidence of Treatment-Emergent Adverse Events Reported for ≥5% of Subjects in Any Treatment Group by System Organ Class or Preferred Term
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Infections and infestations | 401 | 408 |
| Infections and infestations: Nasopharyngitis | 71 | 87 |
| Infections and infestations: Upper respiratory tract infection | 59 | 67 |
| Infections and infestations: Bronchitis | 59 | 45 |
| Investigations | 284 | 290 |
| Investigations: Alanine aminotransferase increased | 97 | 118 |
| Investigations: Aspartate aminotransferase increased | 52 | 63 |
| Musculoskeletal and connective tissue disorders | 149 | 152 |
| Blood and lymphatic system disorders | 125 | 147 |
| Blood and lymphatic system disorders: Leukopenia | 46 | 60 |
| Blood and lymphatic system disorders: Neutropenia | 42 | 57 |
| Metabolism and nutrition disorders | 113 | 135 |
| Gastrointestinal disorders | 100 | 118 |
| Injury, poisoning and procedural complications | 101 | 95 |
| Skin and subcutaneous tissue disorders | 88 | 94 |
| Nervous system disorders | 60 | 81 |
| Respiratory, thoracic and mediastinal disorders | 60 | 68 |
| Vascular disorders | 60 | 68 |
| General disorders and administration site conditions | 54 | 65 |
Incidence of Serious Treatment-Emergent Adverse Events by System Organ Class or Preferred Term. Deaths are included.
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Number of Subjects with at Least One SAE | 129 | 120 |
| Infections and infestations | 40 | 47 |
| Infections and infestations: Pneumonia | 7 | 7 |
| Infections and infestations: Cellulitis | 7 | 4 |
| Infections and infestations: Erysipelas | 5 | 4 |
| Infections and infestations: COVID-19 | 1 | 3 |
| Infections and infestations: Pyelonephritis acute | 2 | 2 |
| Infections and infestations: COVID-19 pneumonia | 2 | 1 |
| Infections and infestations: Pyelonephritis | 2 | 1 |
| Infections and infestations: Sepsis | 0 | 3 |
| Infections and infestations: Abscess limb | 1 | 1 |
| Infections and infestations: Diverticulitis | 1 | 1 |
| Infections and infestations: Osteomyelitis | 1 | 1 |
| Infections and infestations: Abdominal wall abscess | 0 | 1 |
| Infections and infestations: Abscess soft tissue | 0 | 1 |
| Infections and infestations: Acute sinusitis | 0 | 1 |
| Infections and infestations: Atypical pneumonia | 1 | 0 |
| Infections and infestations: Bartholinitis | 0 | 1 |
| Infections and infestations: Bronchitis | 0 | 1 |
| Infections and infestations: Bullous erysipelas | 1 | 0 |
| Infections and infestations: Bursitis infective | 0 | 1 |
| Infections and infestations: Cat scratch disease | 0 | 1 |
| Infections and infestations: Dengue fever | 0 | 1 |
| Infections and infestations: Device related infection | 0 | 1 |
| Infections and infestations: Device related sepsis | 0 | 1 |
| Infections and infestations: Encephalomyelitis | 0 | 1 |
| Infections and infestations: Gangrene | 0 | 1 |
| Infections and infestations: Gastroenteritis | 0 | 1 |
| Infections and infestations: Influenza | 0 | 1 |
| Infections and infestations: Intervertebral discitis | 1 | 0 |
| Infections and infestations: Joint abscess | 1 | 0 |
| Infections and infestations: Latent tuberculosis | 0 | 1 |
| Infections and infestations: Localised infection | 1 | 0 |
| Infections and infestations: Lower respiratory tract infection | 0 | 1 |
| Infections and infestations: Ludwig angina | 1 | 0 |
| Infections and infestations: Medical device site abscess | 0 | 1 |
| Infections and infestations: Necrotising fasciitis | 0 | 1 |
| Infections and infestations: Necrotising soft tissue infection | 0 | 1 |
| Infections and infestations: Post procedural infection | 1 | 0 |
| Infections and infestations: Pulmonary tuberculosis | 0 | 1 |
| Infections and infestations: Renal abscess | 1 | 0 |
| Infections and infestations: Salpingo-oophoritis | 1 | 0 |
| Infections and infestations: Scrotal abscess | 1 | 0 |
| Infections and infestations: Septic shock | 0 | 1 |
| Infections and infestations: Streptococcal sepsis | 1 | 0 |
| Infections and infestations: Tonsillitis | 0 | 1 |
| Infections and infestations: Urinary tract infection | 0 | 1 |
| Infections and infestations: Viral infection | 0 | 1 |
| Infections and infestations: Viral upper respiratory tract infection | 1 | 0 |
| Infections and infestations: Wound infection pseudomonas | 1 | 0 |
| Musculoskeletal and connective tissue disorders | 14 | 11 |
| Musculoskeletal and connective tissue disorders: Osteoarthritis | 6 | 6 |
| Musculoskeletal and connective tissue disorders: Osteonecrosis | 1 | 1 |
| Musculoskeletal and connective tissue disorders: Rheumatoid arthritis | 1 | 1 |
| Musculoskeletal and connective tissue disorders: Arthritis | 1 | 0 |
| Musculoskeletal and connective tissue disorders: Bursitis | 1 | 0 |
| Musculoskeletal and connective tissue disorders: Cervical spinal stenosis | 0 | 1 |
| Musculoskeletal and connective tissue disorders: Foot deformity | 0 | 1 |
| Musculoskeletal and connective tissue disorders: Intervertebral disc protrusion | 1 | 0 |
| Musculoskeletal and connective tissue disorders: Joint ankylosis | 0 | 1 |
| Musculoskeletal and connective tissue disorders: Muscle contracture | 1 | 0 |
| Musculoskeletal and connective tissue disorders: Musculoskeletal chest pain | 1 | 0 |
| Musculoskeletal and connective tissue disorders: Spinal osteoarthritis | 1 | 0 |
| Injury, poisoning and procedural complications | 8 | 14 |
| Injury, poisoning and procedural complications: Clavicle fracture | 1 | 1 |
| Injury, poisoning and procedural complications: Femoral neck fracture | 0 | 2 |
| Injury, poisoning and procedural complications: Head injury | 2 | 0 |
| Injury, poisoning and procedural complications: Hip fracture | 0 | 2 |
| Injury, poisoning and procedural complications: Acetabulum fracture | 0 | 1 |
| Injury, poisoning and procedural complications: Arthropod bite | 1 | 0 |
| Injury, poisoning and procedural complications: Comminuted fracture | 0 | 1 |
| Injury, poisoning and procedural complications: Concussion | 0 | 1 |
| Injury, poisoning and procedural complications: Extradural haematoma | 1 | 0 |
| Injury, poisoning and procedural complications: Femur fracture | 1 | 0 |
| Injury, poisoning and procedural complications: Foot fracture | 0 | 1 |
| Injury, poisoning and procedural complications: Humerus fracture | 0 | 1 |
| Injury, poisoning and procedural complications: Lower limb fracture | 0 | 1 |
| Injury, poisoning and procedural complications: Multiple injuries | 1 | 0 |
| Injury, poisoning and procedural complications: Muscle rupture | 1 | 0 |
| Injury, poisoning and procedural complications: Overdose | 0 | 1 |
| Injury, poisoning and procedural complications: Post procedural complication | 0 | 1 |
| Injury, poisoning and procedural complications: Thoracic vertebral fracture | 0 | 1 |
| Injury, poisoning and procedural complications: Traumatic intracranial haematoma | 0 | 1 |
| Injury, poisoning and procedural complications: Wrist fracture | 0 | 1 |
| Cardiac disorders | 11 | 10 |
| Cardiac disorders: Acute myocardial infarction | 3 | 0 |
| Cardiac disorders: Arrhythmia | 1 | 1 |
| Cardiac disorders: Atrial fibrillation | 0 | 2 |
| Cardiac disorders: Acute coronary syndrome | 0 | 1 |
| Cardiac disorders: Angina unstable | 1 | 0 |
| Cardiac disorders: Atrioventricular block complete | 1 | 0 |
| Cardiac disorders: Atrioventricular block second degree | 1 | 0 |
| Cardiac disorders: Bradycardia | 0 | 1 |
| Cardiac disorders: Cardiac arrest | 1 | 0 |
| Cardiac disorders: Cardiac failure chronic | 0 | 1 |
| Cardiac disorders: Cardiac failure congestive | 0 | 1 |
| Cardiac disorders: Coronary artery occlusion | 1 | 0 |
| Cardiac disorders: Coronary artery stenosis | 0 | 1 |
| Cardiac disorders: Myocardial infarction | 0 | 1 |
| Cardiac disorders: Right ventricular dysfunction | 0 | 1 |
| Cardiac disorders: Sinus tachycardia | 0 | 1 |
| Cardiac disorders: Stress cardiomyopathy | 1 | 0 |
| Cardiac disorders: Supraventricular tachyarrhythmia | 0 | 1 |
| Cardiac disorders: Ventricular fibrillation | 1 | 0 |
| Gastrointestinal disorders | 8 | 12 |
| Gastrointestinal disorders: Diverticular perforation | 1 | 2 |
| Gastrointestinal disorders: Abdominal pain | 1 | 1 |
| Gastrointestinal disorders: Colitis | 1 | 1 |
| Gastrointestinal disorders: Gastritis erosive | 0 | 2 |
| Gastrointestinal disorders: Abdominal hernia obstructive | 1 | 0 |
| Gastrointestinal disorders: Dyspepsia | 0 | 1 |
| Gastrointestinal disorders: Gastric polyps | 1 | 0 |
| Gastrointestinal disorders: Gastric ulcer | 0 | 1 |
| Gastrointestinal disorders: Gastrointestinal disorder | 0 | 1 |
| Gastrointestinal disorders: Intestinal obstruction | 0 | 1 |
| Gastrointestinal disorders: Obstructive pancreatitis | 1 | 0 |
| Gastrointestinal disorders: Pancreatitis acute | 0 | 1 |
| Gastrointestinal disorders: Pancreatitis chronic | 1 | 0 |
| Gastrointestinal disorders: Peptic ulcer | 1 | 0 |
| Gastrointestinal disorders: Salivary gland calculus | 0 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 11 | 8 |
| Neoplasms benign, malignant and unspecified: Meningioma | 1 | 1 |
| Neoplasms benign, malignant and unspecified: Benign neoplasm of thyroid gland | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Central nervous system neoplasm | 0 | 1 |
| Neoplasms benign, malignant and unspecified: Cervix carcinoma stage II | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Clear cell renal cell carcinoma | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Colon cancer | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Endometrial adenocarcinoma | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Endometrial cancer | 0 | 1 |
| Neoplasms benign, malignant and unspecified: Extranodal marginal zone B-cell lymphoma (MALT type) | 0 | 1 |
| Neoplasms benign, malignant and unspecified: Gastric cancer | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Invasive ductal breast carcinoma | 0 | 1 |
| Neoplasms benign, malignant and unspecified: Lung adenocarcinoma stage III | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Malignant melanoma | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Marginal zone lymphoma | 0 | 1 |
| Neoplasms benign, malignant and unspecified: Meningioma benign | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Metastatic neoplasm | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Pancreatic carcinoma metastatic | 0 | 1 |
| Neoplasms benign, malignant and unspecified: Salivary gland cancer | 1 | 0 |
| Neoplasms benign, malignant and unspecified: Uterine leiomyoma | 0 | 1 |
| Nervous system disorders | 13 | 6 |
| Nervous system disorders: Cerebrovascular accident | 4 | 2 |
| Nervous system disorders: Dizziness | 1 | 1 |
| Nervous system disorders: Ischaemic stroke | 0 | 2 |
| Nervous system disorders: Syncope | 2 | 0 |
| Nervous system disorders: Carotid artery aneurysm | 1 | 0 |
| Nervous system disorders: Encephalopathy | 1 | 0 |
| Nervous system disorders: Migraine | 1 | 0 |
| Nervous system disorders: Myelopathy | 1 | 0 |
| Nervous system disorders: Paraesthesia | 1 | 0 |
| Nervous system disorders: Pineal gland cyst | 1 | 0 |
| Nervous system disorders: Seizure | 1 | 0 |
| Nervous system disorders: Subarachnoid haemorrhage | 0 | 1 |
| Nervous system disorders: Transient ischaemic attack | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | 7 | 12 |
| Respiratory, thoracic and mediastinal disorders: Pulmonary embolism | 2 | 4 |
| Respiratory, thoracic and mediastinal disorders: Chronic obstructive pulmonary disease | 1 | 1 |
| Respiratory, thoracic and mediastinal disorders: Pulmonary fibrosis | 1 | 1 |
| Respiratory, thoracic and mediastinal disorders: Respiratory failure | 1 | 1 |
| Respiratory, thoracic and mediastinal disorders: Asthmatic crisis | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders: Bronchitis chronic | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders: Chronic respiratory failure | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders: Chylothorax | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders: effusion | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders: Pleurisy | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders: Pneumothorax | 0 | 1 |
| Investigations | 9 | 6 |
| Investigations: Alanine aminotransferase increased | 7 | 5 |
| Investigations: Hepatic enzyme increased | 1 | 1 |
| Investigations: Liver function test increased | 1 | 0 |
| Hepatobiliary disorders | 6 | 3 |
| Hepatobiliary disorders: Cholelithiasis | 2 | 1 |
| Hepatobiliary disorders: Cholecystitis chronic | 1 | 1 |
| Hepatobiliary disorders: Biliary colic | 1 | 0 |
| Hepatobiliary disorders: Hepatotoxicity | 1 | 0 |
| Hepatobiliary disorders: Hyperplastic cholecystopathy | 0 | 1 |
| Hepatobiliary disorders: Liver injury | 1 | 0 |
| General disorders and administration site conditions | 4 | 4 |
| General disorders and administration site conditions: Death | 1 | 1 |
| General disorders and administration site conditions: Sudden death | 1 | 1 |
| General disorders and administration site conditions: Lithiasis | 1 | 0 |
| General disorders and administration site conditions: Pyrexia | 0 | 1 |
| General disorders and administration site conditions: Sudden cardiac death | 1 | 0 |
| General disorders and administration site conditions: Vascular stent occlusion | 0 | 1 |
| Reproductive system and breast disorders | 3 | 3 |
| Reproductive system and breast disorders: Uterine polyp | 2 | 0 |
| Reproductive system and breast disorders: Endometrial hyperplasia | 0 | 1 |
| Reproductive system and breast disorders: Female genital tract fistula | 0 | 1 |
| Reproductive system and breast disorders: Genital haemorrhage | 1 | 0 |
| Reproductive system and breast disorders: Intermenstrual bleeding | 0 | 1 |
| Reproductive system and breast disorders: Ovarian cyst | 0 | 1 |
| Skin and subcutaneous tissue disorders | 4 | 2 |
| Skin and subcutaneous tissue disorders: Dermatitis | 1 | 1 |
| Skin and subcutaneous tissue disorders: Skin ulcer | 1 | 1 |
| Skin and subcutaneous tissue disorders: Dermatitis contact | 1 | 0 |
| Skin and subcutaneous tissue disorders: Erythema | 1 | 0 |
| Vascular disorders | 4 | 2 |
| Vascular disorders: Deep vein thrombosis | 1 | 0 |
| Vascular disorders: Hypertensive crisis | 1 | 0 |
| Vascular disorders: Peripheral artery occlusion | 0 | 1 |
| Vascular disorders: Shock haemorrhagic | 1 | 0 |
| Vascular disorders: Thrombophlebitis | 0 | 1 |
| Vascular disorders: Varicose vein | 1 | 0 |
| Renal and urinary disorders | 3 | 2 |
| Renal and urinary disorders: Calculus urinary | 1 | 0 |
| Renal and urinary disorders: Nephritis | 1 | 0 |
| Renal and urinary disorders: Nephrolithiasis | 0 | 1 |
| Renal and urinary disorders: Renal colic | 1 | 0 |
| Renal and urinary disorders: Ureterolithiasis | 0 | 1 |
| Blood and lymphatic system disorders | 1 | 2 |
| Blood and lymphatic system disorders: Febrile neutropenia | 0 | 1 |
| Blood and lymphatic system disorders: Lymphadenopathy | 1 | 0 |
| Blood and lymphatic system disorders: Splenic cyst | 0 | 1 |
| Pregnancy, puerperium and perinatal conditions | 2 | 1 |
| Pregnancy, puerperium and perinatal conditions: Abortion spontaneous | 1 | 0 |
| Pregnancy, puerperium and perinatal conditions: Abortion threatened | 1 | 0 |
| Pregnancy, puerperium and perinatal conditions: Ectopic pregnancy | 0 | 1 |
| Ear and labyrinth disorders | 1 | 1 |
| Ear and labyrinth disorders: Deafness neurosensory | 0 | 1 |
| Ear and labyrinth disorders: Vestibular disorder | 1 | 0 |
| Eye disorders | 0 | 2 |
| Eye disorders: Cataract | 0 | 1 |
| Eye disorders: Ocular myasthenia | 0 | 1 |
| Immune system disorders | 1 | 0 |
| Immune system disorders: Hypersensitivity | 1 | 0 |
| Psychiatric disorders | 1 | 0 |
| Psychiatric disorders: Completed suicide | 1 | 0 |
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Infections | 389 | 398 |
| Infections: Opportunistic Infections | 19 | 22 |
| Malignancies | 9 | 6 |
| Basal cell carcinoma | 2 | 1 |
| Elevation of Blood Lipids | 120 | 138 |
| Systemic Injection Reactions and Hypersensitivity Reactions | 99 | 100 |
| Systemic Injection Reactions and Hypersensitivity Reactions: Anaphylactic Reactions | 0 | 0 |
| Gastrointestinal Perforations | 1 | 2 |
| Neutropenia, Thrombocytopenia, Leukocytopenia and Pancytopenia | 146 | 168 |
| Potential Hepatotoxicity | 68 | 63 |
| Injection Site Reactions | 34 | 34 |
| Demyelination in Peripheral or Central Nervous System | 0 | 1 |
| Autoimmune Disorders | 48 | 41 |
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment | 87 | 90 |
Incidence Rate of all Subjects with at Least One Treatment Emergent AE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.
| subjects per 100 subject-years | OKZ 64 mg q4w | OKZ 64 mg q2w |
|---|---|---|
| Incidence Rate of Treatment Emergent AEs Per Patient-years of Exposure | 48.75 | 49.84 |
Incidence Rate of all Subjects with at Least One Treatment Emergent SAE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.
| subjects per 100 subject-years | OKZ 64 mg q4w | OKZ 64 mg q2w |
|---|---|---|
| Incidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure | 7.74 | 7.37 |
Incidence Rate of all Subjects with at Least One Treatment Emergent AESI. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.
| subjects per 100 subject-years | OKZ 64 mg q4w | OKZ 64 mg q2w |
|---|---|---|
| Incidence Rate of Treatment Emergent AESIs (Safety Population) | 40.49 | 42.13 |
Number and Proportion of subjects achieving an ACR20 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Week 12 OLE | 861 | 863 |
| Week 20 OLE | 850 | 851 |
| Week 28 OLE | 839 | 829 |
| Week 40 OLE | 795 | 795 |
| Week 52 OLE | 780 | 783 |
| Week 64 OLE | 777 | 774 |
| Week 82 OLE | 811 | 830 |
Number and Proportion of subjects achieving an ACR50 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 50 % response is a composite defined as a ≥ 50% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Week 12 OLE | 598 | 601 |
| Week 20 OLE | 607 | 607 |
| Week 28 OLE | 597 | 610 |
| Week 40 OLE | 600 | 594 |
| Week 52 OLE | 563 | 606 |
| Week 64 OLE | 584 | 583 |
| Week 82 OLE | 608 | 619 |
Number and Proportion of subjects achieving an ACR70 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82 American College of Rheumatology 70 % response is a composite defined as a ≥ 70% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 70% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Week 12 OLE | 330 | 362 |
| Week 20 OLE | 358 | 353 |
| Week 28 OLE | 367 | 357 |
| Week 40 OLE | 375 | 369 |
| Week 52 OLE | 370 | 387 |
| Week 64 OLE | 373 | 387 |
| Week 82 OLE | 382 | 393 |
The number and proportion of subjects with SDAI score ≤ 3.3 (considered to be in remission). The SDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), CRP (mg/dL), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS) + CRP (mg/dL)
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 0 | 0 |
| OLE Baseline | 137 | 145 |
| Week 12 OLE | 161 | 190 |
| Week 20 OLE | 192 | 197 |
| Week 28 OLE | 196 | 196 |
| Week 40 OLE | 204 | 211 |
| Week 52 OLE | 218 | 225 |
| Week 64 OLE | 223 | 257 |
| Week 82 OLE | 231 | 267 |
Number and Proportion of subjects with DAS28 low disease activity (based on DAS28 C-reactive protein (CRP) \< 3.2), who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82. The DAS28 (CRP) was calculated in the statistical database for analysis purposes using the Swollen joint count (SJC) (28 joints), Tender joint count (TJC) (28 joints), CRP level, and the Patient Global Assessment of Disease Activity Visual Analog Scale (VAS) (100 mm VAS, where 0 is "no disease activity" and 100 was "maximal disease activity") according to the following formula: \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.36 × natural log (CRP+1)\] + \[0.014 × VAS\] + 0.96.
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1 | 1 |
| OLE Baseline | 573 | 537 |
| Week 12 OLE | 681 | 685 |
| Week 20 OLE | 703 | 714 |
| Week 28 OLE | 684 | 694 |
| Week 40 OLE | 688 | 691 |
| Week 52 OLE | 679 | 680 |
| Week 64 OLE | 681 | 678 |
| Week 82 OLE | 706 | 712 |
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| score on a scale | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1.70 ± 0.581 | 1.74 ± 0.561 |
| Week 12 OLE | 1.03 ± 0.632 | 1.00 ± 0.628 |
| Change from Core Baseline | -0.67 ± 0.628 | -0.74 ± 0.648 |
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| score on a scale | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1.70 ± 0.581 | 1.74 ± 0.561 |
| Week 20 OLE | 1.00 ± 0.647 | 0.99 ± 0.621 |
| Change from Core Baseline | -0.70 ± 0.631 | -0.74 ± 0.640 |
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| score on a scale | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1.70 ± 0.581 | 1.74 ± 0.561 |
| Week 28 OLE | 0.99 ± 0.632 | 0.99 ± 0.627 |
| Change from Core Baseline | -0.71 ± 0.645 | -0.75 ± 0.652 |
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| score on a scale | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1.70 ± 0.581 | 1.74 ± 0.561 |
| Week 40 OLE | 0.97 ± 0.651 | 0.99 ± 0.635 |
| Change from Core Baseline | -0.72 ± 0.663 | -0.75 ± 0.672 |
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| score on a scale | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1.70 ± 0.581 | 1.74 ± 0.561 |
| Week 52 OLE | 0.97 ± 0.653 | 0.96 ± 0.623 |
| Change from Core Baseline | -0.72 ± 0.670 | -0.77 ± 0.671 |
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| score on a scale | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1.70 ± 0.581 | 1.74 ± 0.561 |
| Week 64 OLE | 0.95 ± 0.641 | 0.97 ± 0.635 |
| Change from Core Baseline | -0.74 ± 0.643 | -0.77 ± 0.671 |
HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| score on a scale | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline | 1.70 ± 0.581 | 1.74 ± 0.561 |
| Week 82 OLE | 0.97 ± 0.667 | 0.98 ± 0.667 |
| Change from Core Baseline | -0.72 ± 0.680 | -0.74 ± 0.695 |
The number and proportion of subjects with HAQ-DI improvement ≥ 0.22 Against OLE Baseline. HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.
| Participants | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Week 12 OLE | 297 | 324 |
| Week 20 OLE | 319 | 341 |
| Week 28 OLE | 326 | 320 |
| Week 40 OLE | 310 | 333 |
| Week 52 OLE | 322 | 338 |
| Week 64 OLE | 317 | 326 |
| Week 82 OLE | 326 | 373 |
CDAI Range: 0 (the best outcome) - 76 (the worst outcome), with a decrease from baseline indicating improvement. The CDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: CDAI = SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS)
| index units | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Core Baseline Actual Values | 40.20 ± 11.252 | 40.06 ± 11.605 |
| Week 12 OLE Actual Values | 10.92 ± 9.349 | 10.54 ± 9.106 |
| Change from Core Baseline at week 12 | -29.35 ± 12.093 | -29.54 ± 12.946 |
| Week 20 OLE Actual Values | 10.30 ± 9.489 | 9.90 ± 8.755 |
| Change from Core Baseline at week 20 | -29.87 ± 12.553 | -30.23 ± 12.821 |
| Week 28 OLE Actual Values | 9.77 ± 8.583 | 9.85 ± 8.696 |
| Change from Core Baseline at week 28 | -30.35 ± 12.111 | -30.36 ± 12.849 |
| Week 40 OLE Actual Values | 9.19 ± 8.498 | 9.34 ± 8.235 |
| Change from Core Baseline at week 40 | -30.88 ± 11.992 | -30.80 ± 13.025 |
| Week 52 OLE Actual Values | 8.69 ± 7.954 | 8.61 ± 7.776 |
| Change from Core Baseline at week 52 | -31.35 ± 11.855 | -31.60 ± 12.639 |
| Week 64 OLE Actual Values | 8.42 ± 7.997 | 8.36 ± 7.798 |
| Change from Core Baseline at week 64 | -31.68 ± 11.896 | -31.85 ± 12.484 |
| Week 82 OLE Actual Values | 9.66 ± 10.513 | 9.36 ± 10.236 |
| Change from Core Baseline at week 82 | -30.48 ± 12.878 | -30.58 ± 14.404 |
Collected over Adverse events (AEs) and serious adverse events (SAEs) were reported from OLE Baseline (the same visit as the Week 24 visit in the core studies) until the end of the follow-up period (safety follow-up (SFU-3)). Any AE, including any AE still ongoing at the end of the study, was to be followed until it had resolved, it had a stable sequelae, the Investigator determined that it was no longer clinically significant, or the subject was lost to follow-up.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm 1: OKZ 64 mg q4w + MTX | 13/1,043 (1.2%) | 129/1,043 (12.4%) | 356/1,043 (34.1%) |
| Treatment Arm 2: OKZ 64 mg q2w + MTX | 13/1,061 (1.2%) | 120/1,061 (11.3%) | 386/1,061 (36.4%) |
| Event | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| PneumoniaInfections and infestations | 7/1043 | 7/1061 |
| CellulitisInfections and infestations | 7/1043 | 4/1061 |
| Alanine aminotransferase increasedInvestigations | 7/1043 | 5/1061 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 6/1043 | 6/1061 |
| ErysipelasInfections and infestations | 5/1043 | 4/1061 |
| Cerebrovascular accidentNervous system disorders | 4/1043 | 2/1061 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/1043 | 4/1061 |
| Acute myocardial infarctionCardiac disorders | 3/1043 | 0/1061 |
| COVID-19Infections and infestations | 1/1043 | 3/1061 |
| SepsisInfections and infestations | 0/1043 | 3/1061 |
| Event | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 95/1043 | 115/1061 |
| NasopharyngitisInfections and infestations | 71/1043 | 87/1061 |
| Upper respiratory tract infectionInfections and infestations | 59/1043 | 67/1061 |
| Aspartate aminotransferase increasedInvestigations | 52/1043 | 63/1061 |
| BronchitisInfections and infestations | 59/1043 | 45/1061 |
| LeukopeniaBlood and lymphatic system disorders | 46/1043 | 60/1061 |
| NeutropeniaBlood and lymphatic system disorders | 42/1043 | 57/1061 |
| LymphopeniaBlood and lymphatic system disorders | 41/1043 | 50/1061 |
| HypertensionVascular disorders | 32/1043 | 44/1061 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 25/1043 | 42/1061 |
Subjects who received OKZ in the core study received the same OKZ treatment regimen in the OLE study. Subjects who received in the core study placebo or adalimumab were randomized 1:1 to OKZ 64 mg q2w or OKZ 64 mg q4w regimens in the OLE study. The mITT population included all subjects who signed an ICF for participation in the OLE study, were randomized in the OLE study, received at least 1 dose of study treatment in the OLE study (1057 subjects (OKZ 64 mg q4w), 1047 subjects (OKZ 64 mg q2w)).
| Age, Continuous(years) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX | Total |
|---|---|---|---|
| Mean | 53.7 ± 12.05 | 53.7 ± 11.78 | 53.7 ± 11.91 |
| Sex: Female, Male(Participants) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX | Total |
|---|---|---|---|
| Female | 851 | 840 | 1691 |
| Male | 206 | 207 | 413 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX | Total |
|---|---|---|---|
| Hispanic or Latino | 357 | 332 | 689 |
| Not Hispanic or Latino | 700 | 715 | 1415 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX | Total |
|---|---|---|---|
| Asian | 15 | 17 | 32 |
| Black or African American | 31 | 46 | 77 |
| White | 914 | 896 | 1810 |
| Other/Mixed | 97 | 88 | 185 |
| Region of Enrollment(Participants) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX | Total |
|---|---|---|---|
| Colombia | 32 | 32 | 64 |
| Argentina | 81 | 73 | 154 |
| Hungary | 31 | 36 | 67 |
| United States | 150 | 155 | 305 |
| Czechia | 105 | 94 | 199 |
| United Kingdom | 3 | 6 | 9 |
| Belarus | 9 | 9 | 18 |
| Russia | 217 | 208 | 425 |
| Latvia | 1 | 2 | 3 |
| South Korea | 6 | 6 | 12 |
| Taiwan | 4 | 4 | 8 |
| Brazil | 55 | 61 | 116 |
| Poland | 138 | 133 | 271 |
| Mexico | 137 | 127 | 264 |
| Bulgaria | 36 | 41 | 77 |
| Lithuania | 29 | 38 | 67 |
| Germany | 16 | 20 | 36 |
| Estonia | 7 | 2 | 9 |
| Body Mass Index (BMI)(kg/m^2) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Treatment Arm 2: OKZ 64 mg q2w + MTX | Total |
|---|---|---|---|
| Mean | 28.201 (14.88 to 56.25) | 28.229 (15.62 to 62.22) | 28.215 (14.88 to 62.22) |
Showing the first 100 of 239 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Sep 2021, 49 months.
Results were first posted in Jun 2022, 9 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 49 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab